Active	Status	Sponsor type	Region	Phase	Filter
2 Active 7 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DVX201 / Coeptis
NCT04900454: Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19	Completed	1	12	US	DVX201	Coeptis Therapeutics, Fred Hutchinson Cancer Center	COVID-19 Pneumonia	06/22	07/22
NCT04901416: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS	Completed	1	8	US	DVX201	Coeptis Therapeutics, Duke University	AML, Adult Recurrent, MDS	10/23	06/24
CD38-GEAR-NK / Coeptis
No trials found
Undisclosed SNAP-CAR T therapy / Coeptis
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
DVX201 / Coeptis
NCT04900454: Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19	Completed	1	12	US	DVX201	Coeptis Therapeutics, Fred Hutchinson Cancer Center	COVID-19 Pneumonia	06/22	07/22
NCT04901416: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS	Completed	1	8	US	DVX201	Coeptis Therapeutics, Duke University	AML, Adult Recurrent, MDS	10/23	06/24
CD38-GEAR-NK / Coeptis
No trials found
Undisclosed SNAP-CAR T therapy / Coeptis
No trials found